Barinthus Biotherapeutics (NASDAQ:BRNS) has entered into a proposed all-stock business combination with Clywedog, a strategic move aimed at consolidating resources and advancing a diversified immunotherapy pipeline.
Purple Biotech (NASDAQ:PPBT) posted a net loss of $26.4 million for the full year 2025, a result heavily impacted by a $20.5 million non-cash impairment of its CM24 and NT219 programs.
Xenetic Biosciences (NASDAQ:XBIO) reported a 19% increase in royalty revenue for the full year 2025, providing a financial cushion as the company moves closer to human clinical trials for its lead immuno-oncology program.
bioAffinity Technologies (NASDAQ:BIAF) reported fiscal year 2025 results that underscore an aggressive transition from a broad laboratory service model to a specialized, high-growth diagnostic powerhouse focused on early-stage lung cancer detection.
Savara (NASDAQ:SVRA) provided a year-end financial update that underscores the company’s transition toward the commercial stage, with increased spending on pre-launch activities for its lead drug candidate, molgramostim.
Acurx Pharmaceuticals (NASDAQ:ACXP) on Friday reported a full-year 2025 net loss of $8 million, with cash and cash equivalents of $7.6 million as of December 31, 2025, supported by approximately $4 million in gross proceeds from its equity line of credit during the year.
AC Immune (NASDAQ:ACIU) unveiled clinical data on Friday suggesting its experimental vaccine could potentially slow the progression of Parkinson’s disease, a milestone that accompanied a significant corporate restructuring aimed at preserving its capital.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) has secured a long-term financial runway, shifting focus toward pivotal data readouts for its lead gastrointestinal program following a successful fourth quarter and a transformative February financing.
Precision BioSciences (NASDAQ:DTIL) reported a sharp swing to profitability in its final quarter of 2025, a result primarily driven by the recognition of deferred revenue from its heavyweight partnerships in the genome-editing space.
ProQR Therapeutics (NASDAQ:PRQR), a Leiden, Netherlands-based clinical-stage biotechnology company developing RNA-based therapies for severe genetic rare diseases, on Thursday reported a net loss of $9.1 million for its fourth quarter ended December 31, 2025.
Burning Rock Biotech (NASDAQ:BNR) on Thursday reported unaudited financial results for the fourth quarter and full year ended December 31, 2025, showing modest top-line growth alongside significant margin expansion and cost discipline in its precision oncology testing business.
Seres Therapeutics (NASDAQ:MCRB) delivered a rare profitable year in 2025, though the black ink was the result of a major divestiture rather than a surge in drug sales.
